	US 12,453,758 B2
	Method of using a GIP/GLP1 co-agonist for diabetes
Jorge Alsina-Fernandez, Indianapolis, IN (US); Over Cabrera, Carmel, IN (US); and Tamer Coskun, Carmel, IN (US)
Assigned to ELI LILLY AND COMPANY, Indianapolis, IN (US)
Filed by Eli Lilly and Company, Indianapolis, IN (US)
Filed on Apr. 2, 2025, as Appl. No. 19/098,553.
Application 19/098,553 is a division of application No. 17/260,279, granted, now 12,295,987, previously published as PCT/US2019/042824, filed on Jul. 22, 2019.
Claims priority of provisional application 62/740,640, filed on Oct. 3, 2018.
Claims priority of provisional application 62/730,562, filed on Sep. 13, 2018.
Claims priority of provisional application 62/702,180, filed on Jul. 23, 2018.
Prior Publication US 2025/0241995 A1, Jul. 31, 2025
Int. Cl. A61K 38/26 (2006.01); A61P 3/10 (2006.01)

CPC A61K 38/26 (2013.01) [A61P 3/10 (2018.01)]

8 Claims

1. A method of improving weight management in a patient in need thereof, comprising:

a) administering to said patient a first dose of a GIP:GLP-1 Peptide having a GIP:GLP-1 receptor agonist potency ratio that is greater than or equal to the GIP:GLP-1 receptor agonist potency ratio of a GIP:GLP-1 Peptide having SEQ ID NO: 56 and less than the GIP:GLP-1 receptor agonist potency ratio of a GIP:GLP-1 Peptide having SEQ ID NO: 49, wherein the GIP:GLP-1 agonist potency ratio is measured after a 60 minute incubation using a casein cAMP assay normalized against GIP and GLP-1; and thereafter

b) administering to said patient a second dose of the GIP:GLP-1 Peptide for a minimum of about two weeks; and thereafter

c) administering to said patient a third dose of the GIP:GLP-1 Peptide for a minimum of about two weeks; and thereafter

d) administering to said patient a fourth dose of the GIP:GLP-1 Peptide;

wherein the first dose is about 25% of the fourth dose, the second dose is about 50% of the fourth dose and the third dose is about 75% of the fourth dose.